share_log

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A：股东委托书决议
美股SEC公告 ·  07/30 17:11
Moomoo AI 已提取核心信息
Exicure, Inc., a biotechnology company, has announced a Special Meeting of Stockholders to be held virtually on August 15, 2024. The primary agenda for the meeting is to seek approval for a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors. This strategic move aims to comply with Nasdaq's minimum bid price requirement and improve the stock's marketability. The company's common stock has been under the required $1.00 per share, prompting a potential delisting from Nasdaq. Exicure received a notification from Nasdaq on September 13, 2023, and was given until September 9, 2024, to regain compliance. The reverse stock split is intended to increase the per-share price to...Show More
Exicure, Inc., a biotechnology company, has announced a Special Meeting of Stockholders to be held virtually on August 15, 2024. The primary agenda for the meeting is to seek approval for a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors. This strategic move aims to comply with Nasdaq's minimum bid price requirement and improve the stock's marketability. The company's common stock has been under the required $1.00 per share, prompting a potential delisting from Nasdaq. Exicure received a notification from Nasdaq on September 13, 2023, and was given until September 9, 2024, to regain compliance. The reverse stock split is intended to increase the per-share price to meet Nasdaq's listing standards. Stockholders of record as of July 26, 2024, are eligible to vote at the meeting. The Board recommends voting in favor of the reverse stock split. The meeting will also address any other business that may properly come before it. Voting can be done electronically during the meeting or by proxy via telephone, internet, or mail as detailed in the Proxy Statement.
生物技术公司Exicure, Inc.宣布将于2024年8月15日以线上方式举行特别股东大会。会议主要议程是寻求股东批准公司普通股的反向拆股，比例范围为1股拆成2股至1股拆成15股，由董事会决定。此战略举措旨在遵守纳斯达克的最低买盘价要求并提高股票的市场流通性。公司的普通股价格一直低于所需的1.00美元/股，可能会导致纳斯达克摘牌。Exicure于2023年9月13日收到纳斯达克的通知，并被给予直至2024年9月9日重新符合规定的时间。反向拆股旨在增加每股价格以符合纳斯达克的上市标准。截至2024年7月26日的持股人有资格在会议上投票。董事会建议投票支持反向拆股。会议还将讨论其他任何适当的业务。投票可以在会议期间通过电子方式进行，也可以根据代理声明通过电话、互联网或邮件进行。
生物技术公司Exicure, Inc.宣布将于2024年8月15日以线上方式举行特别股东大会。会议主要议程是寻求股东批准公司普通股的反向拆股，比例范围为1股拆成2股至1股拆成15股，由董事会决定。此战略举措旨在遵守纳斯达克的最低买盘价要求并提高股票的市场流通性。公司的普通股价格一直低于所需的1.00美元/股，可能会导致纳斯达克摘牌。Exicure于2023年9月13日收到纳斯达克的通知，并被给予直至2024年9月9日重新符合规定的时间。反向拆股旨在增加每股价格以符合纳斯达克的上市标准。截至2024年7月26日的持股人有资格在会议上投票。董事会建议投票支持反向拆股。会议还将讨论其他任何适当的业务。投票可以在会议期间通过电子方式进行，也可以根据代理声明通过电话、互联网或邮件进行。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息